Mechanism for improved cardiac performance with arteriolar dilators in aortic insufficiency

B. H. Greenberg, H. DeMots, Edward Murphy, S. H. Rahimtoola

    Research output: Contribution to journalArticle

    45 Citations (Scopus)

    Abstract

    To determine how arteriolar dilation improves cardiac performance in aortic insufficiency, we evaluated the acute effects of hydralazine in 10 patients with chronic severe aortic insufficiency. Control measurements of intracardiac and intravascular pressures, cardiac output and left ventricular volumes were obtained at cardiac catheterization. Hydralazine, 0.3 mg/kg i.v. (maximal dose 20 mg), was administered and all measurements were repeated 30 minutes later. A reduction in systemic vascular resistance from 1264 to 710 dyn-sec-cm-5 was associated with significant increases in forward cardiac index (2.9 to 5.1 l/min2) and stroke volume index (37 to 55 ml/m2). Left ventricular end-diastolic pressure was reduced from 19 to 12 mm Hg. There was a significant reduction in mean arterial pressure (88 to 83 mm Hg) and a significant increase in heart rate (81 to 94 beats/min). Regurgitant stroke volume was reduced by more than 10 ml/m2 in seven patients and for the group was significantly reduced, from 65 to 53 ml/m2. Regurgitant fraction was reduced in all patients; the overall reduction from 0.64 to 0.48 was highly significant. Ejection fraction increased more than 0.10 in four patients, by 0.08 in additional patient and for the group increased significantly from 0.50 to 0.57. Left ventricular end-diastolic volume decreased by more than 25 ml/m2 in four patients, by 19 ml/m2 in an additional patient and was decreased significantly, from 208 to 190 ml/m2, for the group. Arteriolar dilators improve cardiac performance in aortic insufficiency by reducing the amount of aortic regurgitation and, in some patients, by substantially improving systolic pump function. These data suggest a role for arteriolar dilators in the management of selected patients with aortic insufficiency.

    Original languageEnglish (US)
    Pages (from-to)263-268
    Number of pages6
    JournalCirculation
    Volume63
    Issue number2
    StatePublished - 1981

    Fingerprint

    Stroke Volume
    Hydralazine
    Aortic Valve Insufficiency
    Cardiac Catheterization
    Cardiac Output
    Vascular Resistance
    Dilatation
    Arterial Pressure
    Heart Rate
    Blood Pressure
    Pressure

    ASJC Scopus subject areas

    • Physiology
    • Cardiology and Cardiovascular Medicine

    Cite this

    Greenberg, B. H., DeMots, H., Murphy, E., & Rahimtoola, S. H. (1981). Mechanism for improved cardiac performance with arteriolar dilators in aortic insufficiency. Circulation, 63(2), 263-268.

    Mechanism for improved cardiac performance with arteriolar dilators in aortic insufficiency. / Greenberg, B. H.; DeMots, H.; Murphy, Edward; Rahimtoola, S. H.

    In: Circulation, Vol. 63, No. 2, 1981, p. 263-268.

    Research output: Contribution to journalArticle

    Greenberg, BH, DeMots, H, Murphy, E & Rahimtoola, SH 1981, 'Mechanism for improved cardiac performance with arteriolar dilators in aortic insufficiency', Circulation, vol. 63, no. 2, pp. 263-268.
    Greenberg, B. H. ; DeMots, H. ; Murphy, Edward ; Rahimtoola, S. H. / Mechanism for improved cardiac performance with arteriolar dilators in aortic insufficiency. In: Circulation. 1981 ; Vol. 63, No. 2. pp. 263-268.
    @article{2e41beff9e5f44ca867247ae5d1c5e5b,
    title = "Mechanism for improved cardiac performance with arteriolar dilators in aortic insufficiency",
    abstract = "To determine how arteriolar dilation improves cardiac performance in aortic insufficiency, we evaluated the acute effects of hydralazine in 10 patients with chronic severe aortic insufficiency. Control measurements of intracardiac and intravascular pressures, cardiac output and left ventricular volumes were obtained at cardiac catheterization. Hydralazine, 0.3 mg/kg i.v. (maximal dose 20 mg), was administered and all measurements were repeated 30 minutes later. A reduction in systemic vascular resistance from 1264 to 710 dyn-sec-cm-5 was associated with significant increases in forward cardiac index (2.9 to 5.1 l/min2) and stroke volume index (37 to 55 ml/m2). Left ventricular end-diastolic pressure was reduced from 19 to 12 mm Hg. There was a significant reduction in mean arterial pressure (88 to 83 mm Hg) and a significant increase in heart rate (81 to 94 beats/min). Regurgitant stroke volume was reduced by more than 10 ml/m2 in seven patients and for the group was significantly reduced, from 65 to 53 ml/m2. Regurgitant fraction was reduced in all patients; the overall reduction from 0.64 to 0.48 was highly significant. Ejection fraction increased more than 0.10 in four patients, by 0.08 in additional patient and for the group increased significantly from 0.50 to 0.57. Left ventricular end-diastolic volume decreased by more than 25 ml/m2 in four patients, by 19 ml/m2 in an additional patient and was decreased significantly, from 208 to 190 ml/m2, for the group. Arteriolar dilators improve cardiac performance in aortic insufficiency by reducing the amount of aortic regurgitation and, in some patients, by substantially improving systolic pump function. These data suggest a role for arteriolar dilators in the management of selected patients with aortic insufficiency.",
    author = "Greenberg, {B. H.} and H. DeMots and Edward Murphy and Rahimtoola, {S. H.}",
    year = "1981",
    language = "English (US)",
    volume = "63",
    pages = "263--268",
    journal = "Circulation",
    issn = "0009-7322",
    publisher = "Lippincott Williams and Wilkins",
    number = "2",

    }

    TY - JOUR

    T1 - Mechanism for improved cardiac performance with arteriolar dilators in aortic insufficiency

    AU - Greenberg, B. H.

    AU - DeMots, H.

    AU - Murphy, Edward

    AU - Rahimtoola, S. H.

    PY - 1981

    Y1 - 1981

    N2 - To determine how arteriolar dilation improves cardiac performance in aortic insufficiency, we evaluated the acute effects of hydralazine in 10 patients with chronic severe aortic insufficiency. Control measurements of intracardiac and intravascular pressures, cardiac output and left ventricular volumes were obtained at cardiac catheterization. Hydralazine, 0.3 mg/kg i.v. (maximal dose 20 mg), was administered and all measurements were repeated 30 minutes later. A reduction in systemic vascular resistance from 1264 to 710 dyn-sec-cm-5 was associated with significant increases in forward cardiac index (2.9 to 5.1 l/min2) and stroke volume index (37 to 55 ml/m2). Left ventricular end-diastolic pressure was reduced from 19 to 12 mm Hg. There was a significant reduction in mean arterial pressure (88 to 83 mm Hg) and a significant increase in heart rate (81 to 94 beats/min). Regurgitant stroke volume was reduced by more than 10 ml/m2 in seven patients and for the group was significantly reduced, from 65 to 53 ml/m2. Regurgitant fraction was reduced in all patients; the overall reduction from 0.64 to 0.48 was highly significant. Ejection fraction increased more than 0.10 in four patients, by 0.08 in additional patient and for the group increased significantly from 0.50 to 0.57. Left ventricular end-diastolic volume decreased by more than 25 ml/m2 in four patients, by 19 ml/m2 in an additional patient and was decreased significantly, from 208 to 190 ml/m2, for the group. Arteriolar dilators improve cardiac performance in aortic insufficiency by reducing the amount of aortic regurgitation and, in some patients, by substantially improving systolic pump function. These data suggest a role for arteriolar dilators in the management of selected patients with aortic insufficiency.

    AB - To determine how arteriolar dilation improves cardiac performance in aortic insufficiency, we evaluated the acute effects of hydralazine in 10 patients with chronic severe aortic insufficiency. Control measurements of intracardiac and intravascular pressures, cardiac output and left ventricular volumes were obtained at cardiac catheterization. Hydralazine, 0.3 mg/kg i.v. (maximal dose 20 mg), was administered and all measurements were repeated 30 minutes later. A reduction in systemic vascular resistance from 1264 to 710 dyn-sec-cm-5 was associated with significant increases in forward cardiac index (2.9 to 5.1 l/min2) and stroke volume index (37 to 55 ml/m2). Left ventricular end-diastolic pressure was reduced from 19 to 12 mm Hg. There was a significant reduction in mean arterial pressure (88 to 83 mm Hg) and a significant increase in heart rate (81 to 94 beats/min). Regurgitant stroke volume was reduced by more than 10 ml/m2 in seven patients and for the group was significantly reduced, from 65 to 53 ml/m2. Regurgitant fraction was reduced in all patients; the overall reduction from 0.64 to 0.48 was highly significant. Ejection fraction increased more than 0.10 in four patients, by 0.08 in additional patient and for the group increased significantly from 0.50 to 0.57. Left ventricular end-diastolic volume decreased by more than 25 ml/m2 in four patients, by 19 ml/m2 in an additional patient and was decreased significantly, from 208 to 190 ml/m2, for the group. Arteriolar dilators improve cardiac performance in aortic insufficiency by reducing the amount of aortic regurgitation and, in some patients, by substantially improving systolic pump function. These data suggest a role for arteriolar dilators in the management of selected patients with aortic insufficiency.

    UR - http://www.scopus.com/inward/record.url?scp=0019366253&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0019366253&partnerID=8YFLogxK

    M3 - Article

    C2 - 7449051

    AN - SCOPUS:0019366253

    VL - 63

    SP - 263

    EP - 268

    JO - Circulation

    JF - Circulation

    SN - 0009-7322

    IS - 2

    ER -